Literature DB >> 2205652

Differential human serologic response to two 60,000 molecular weight Chlamydia trachomatis antigens.

E A Wagar1, J Schachter, P Bavoil, R S Stephens.   

Abstract

Chlamydia trachomatis causes sexually transmitted diseases and is associated with serious long-term sequelae such as tubal infertility and ectopic pregnancy. There have been suggestions that chlamydial antigens of approximately 57,000-60,000 Mr may be involved in the immunopathology. Two important chlamydial antigens of 57,000-60,000 Mr are a Triton X-100-soluble antigen, which induces hypersensitivity in ocular models, and a sarcosyl-insoluble cysteine-rich structural protein, omp2. In this study, a 57,000 Mr Triton X-100-soluble protein was characterized as the chlamydial homolog of groEL, a heat shock protein. Using protein fractions, antibody responses of pelvic inflammatory disease (PID) and ectopic pregnancy patients to chlamydial groEL and omp2 were differentiated. Nearly all patients in both groups were reactive to omp2. Of those with titers greater than or equal to 1:512, 31% of PID sera and 81% of ectopic pregnancy sera were positive for chlamydial groEL (P = .004). This selectivity suggests that women with PID who develop chronic sequelae are those with antibody to groEL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205652     DOI: 10.1093/infdis/162.4.922

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

1.  Immunization with a peptide corresponding to chlamydial heat shock protein 60 increases the humoral immune response in C3H mice to a peptide representing variable domain 4 of the major outer membrane protein of Chlamydia trachomatis.

Authors:  V L Motin; L M de la Maza; E M Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Stress response gene regulation in Chlamydia is dependent on HrcA-CIRCE interactions.

Authors:  Adam C Wilson; Ming Tan
Journal:  J Bacteriol       Date:  2004-06       Impact factor: 3.490

3.  Chlamydial GroEL autoregulates its own expression through direct interactions with the HrcA repressor protein.

Authors:  Adam C Wilson; Christine C Wu; John R Yates; Ming Tan
Journal:  J Bacteriol       Date:  2005-11       Impact factor: 3.490

4.  Sequence diversity of the 60-kilodalton protein and of a putative 15-kilodalton protein between the trachoma and lymphogranuloma venereum biovars of Chlamydia trachomatis.

Authors:  L M de la Maza; T J Fielder; E J Carlson; B A Markoff; E M Peterson
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

Review 5.  Beyond the bacterium: planctomycetes challenge our concepts of microbial structure and function.

Authors:  John A Fuerst; Evgeny Sagulenko
Journal:  Nat Rev Microbiol       Date:  2011-06       Impact factor: 60.633

6.  Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis.

Authors:  S Pal; T J Fielder; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  An in vitro model for immune control of chlamydial growth in polarized epithelial cells.

Authors:  J U Igietseme; P B Wyrick; D Goyeau; R G Rank
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Murine cytotoxic T lymphocytes induced following Chlamydia trachomatis intraperitoneal or genital tract infection respond to cells infected with multiple serovars.

Authors:  M N Starnbach; M J Bevan; M F Lampe
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Production of Chlamydia pneumoniae proteins in Bacillus subtilis and their use in characterizing immune responses in the experimental infection model.

Authors:  Ulla Airaksinen; Tuula Penttilä; Eva Wahlström; Jenni M Vuola; Mirja Puolakkainen; Matti Sarvas
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

10.  Characterization of two conformational epitopes of the Chlamydia trachomatis serovar L2 DnaK immunogen.

Authors:  S Birkelund; P Mygind; A Holm; B Larsen; F Beck; G Christiansen
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.